Psy84 - Impact of High Discontinuation Rates for Secukinumab on Average Costs and Cost-Effectiveness Relative to Other Biological Treatments of Moderate-To-Severe Plaque Psoriasis in Sweden
Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2659
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Elsevier BV